Roche Australia has announced the Australian Therapeutic Goods Administration (TGA) has registered Vabysmo (faricimab) for the treatment of neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular oedema (DMO). Read more
The suppliers of two new anti-VEGF therapies recently cleared in the US that work to reduce macular disease treatment burdens are seeking approval to list the treatments on the Australian Pharmaceutical Benefits Scheme (PBS). Read more
The US Food and Drug Administration (FDA) has approved the Susvimo implant which delivers ranibizumab continuously, offering patients living with neovascular age-related macular degeneration (nAMD) an alternative to more frequent anti-VEGF eye injections. Read more
Prominent Melbourne retinal disease researcher Professor Robyn Guymer is encouraged by the Phase 3 results of a trial she’s been involved in, investigating a new therapy she says is the only intervention shown to significantly slow the growth of lesions in dry AMD. Read more
A clinical trial at Sydney Eye Hospital is evaluating the safety and efficacy of using infrared light to treat macular oedema from retinal vein occlusions, instead of the current standard treatment of eye injections. Read more
Eight Australian researchers are taking their projects to the next level with a share of more than $1 million in research funding from Macular Disease Foundation Australia (MDFA). Read more
As part of Macula Month this May, Insight examines drug development programs that could significantly alter the late-stage AMD therapy landscape. Leading experts also discuss why optometrists are such an important link in the success of both patient outcomes and clinical trials.
Australia’s first clinical trials of an investigational gene therapy for dry age-related macular degeneration (AMD) has commenced at the Centre for Eye Research Australia (CERA). Read more
An independent expert panel has recommended Novartis’ treatment Beovu be subsidised through the Pharmaceutical Benefits Scheme (PBS) for neovascular age-related macular degeneration (nAMD) patients as a second-line anti-VEGF treatment. Read more
Two years since the KeepSight launch, Insight asks what measurable difference this once-in-a-generation program is making to those living with the diabetes.